Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company that regularly issues news updates about its progress in developing therapies for autoimmune, inflammatory, and other immune-mediated diseases. The company’s announcements frequently focus on its lead program, SL-325, a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to target the clinically validated DR3/TL1A pathway in inflammatory bowel disease (IBD) and related conditions.
News about Shattuck often covers key clinical and regulatory milestones for SL-325, including Investigational New Drug (IND) submissions, IND clearance, initiation of Phase 1 clinical trials in healthy volunteers, and dosing of the first participants. The company also reports on preclinical data for SL-325, such as high-affinity binding to DR3, potent inhibition of TL1A binding, and favorable safety and receptor occupancy findings in non-human primate studies.
Investors following STTK can also expect updates on Shattuck’s broader DR3-focused pipeline, including multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and another biologically relevant target for IBD. Financing news is another recurring theme, with press releases detailing private placements, expected use of proceeds to advance SL-325 through Phase 1 and planned Phase 2 trials, and the company’s views on its cash runway.
Additional news items highlight Shattuck’s participation in medical and investor conferences, key opinion leader panels on DR3/TL1A biology and IBD, and changes to its Board of Directors associated with major financings. For readers tracking STTK, this page provides a centralized view of Shattuck’s clinical progress, scientific presentations, capital-raising activities, and governance developments as disclosed in its public communications.
Austin, TX and Durham, NC – November 6, 2020 – Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, announced participation in the Cowen 4th Annual IO Next Summit on November 13, 2020. CEO Taylor Schreiber and senior executives will join a fireside chat with analyst Marc Frahm. The presentation is scheduled for 2:15 p.m. EST and can be accessed via a webcast. Shattuck's innovative ARC® platform develops therapies inhibiting immune checkpoints while activating costimulatory pathways.
Summary not available.
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its upcoming presentation at the virtual CD47|SIRPα Summit 2020 on November 5, 2020. The presentation, titled "CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity," will be delivered by CEO Taylor Schreiber at 10:45 a.m. EST. Shattuck is developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program SL-172154 currently in a Phase 1 trial.
Shattuck Labs, a clinical-stage biotechnology company, will present at the TIGIT Therapies Digital Summit 2020 on October 26 at 10:00 a.m. EDT. The presentation, titled Using LIGHT to Hotwire TIGIT Blockade, will be led by CEO Taylor Schreiber. Shattuck is focused on developing bi-functional fusion proteins for cancer and autoimmune treatments through its unique ARC® platform. Their leading compound, SL-172154, is currently in a Phase 1 trial, alongside another compound, SL-279252, being tested with Takeda Pharmaceuticals. The presentation will be available for download on their website.
Shattuck Labs announced the successful closing of its upsized initial public offering, consisting of 13,664,704 shares at $17.00 each, garnering approximately $232.3 million in gross proceeds. The offering included the full exercise of underwriters' options for an additional 1,782,352 shares. All shares were offered by Shattuck, with trading on Nasdaq under the symbol STTK commencing on October 9, 2020. The company focuses on developing bi-functional fusion proteins for cancer and autoimmune disease treatments, with key programs currently in Phase 1 trials.
Shattuck Labs has announced the pricing of its upsized initial public offering, offering 11,882,352 shares of common stock at $17.00 each, aiming for gross proceeds of approximately $202 million. The shares will commence trading on Nasdaq under the symbol STTK on October 9, 2020. An additional 1,782,352 shares may be purchased by underwriters within 30 days of the offering. The offering is set to close on October 14, 2020, subject to customary conditions. Citigroup, Cowen, and Evercore ISI are joint book-running managers for this offering.